If intimacy used to feel easy and now feels uncomfortable or far away, you are not imagining it, and you are not alone. Wanting closeness at 47 or 58 is not something to apologize for; it is part of being fully alive.
Two different problems that often travel together
Women often describe "things changing down there" and "not feeling interested anymore" in the same breath, but a provider usually separates them, because they have different causes and different approaches.
The physical layer is what clinicians now call the *genitourinary syndrome of menopause* (GSM). As estrogen declines, the tissues of the vulva, vagina, and lower urinary tract become thinner, less elastic, and less lubricated. This can show up as dryness, burning, discomfort with intimacy, and more frequent urinary symptoms. GSM is common and tends to be progressive without support, unlike hot flashes, which often fade with time [1][2].
The desire layer is more complex. Libido after midlife is shaped by hormones, yes, but also by sleep, stress, mood, medications (including some antidepressants and blood pressure drugs), thyroid function, relationship dynamics, and—very practically—whether intimacy has started to *hurt*. Pain quietly teaches the body to avoid, and avoidance can look like "lost desire" when the real driver is discomfort [3].
This distinction matters. Sometimes addressing comfort reopens the door to desire on its own. Sometimes the desire question needs its own attention. A good evaluation looks at both.
Source: [1] The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society, [3] Female Sexual Dysfunction: ACOG Practice Bulletin
What an independent provider reviews first
Before suggesting any support, a thoughtful provider tends to rule things out rather than reach for a single answer.
- History and timeline. When did things change—abruptly (surgery, a new medication) or gradually (the menopause transition)? Is the main issue comfort, interest, arousal, or distress about the change?
- Medications and health conditions. Certain antidepressants, hormonal contraceptives in earlier years, and other drugs can blunt desire or arousal. Thyroid disease, diabetes, and depression all overlap with low libido [3].
- Symptom mapping for GSM. Dryness, irritation, discomfort with intimacy, and urinary symptoms point toward genitourinary changes that may respond to local approaches [1][2].
- Labs where relevant. There is no single "libido level" to measure, and routine androgen testing is not recommended to diagnose low desire. However, a provider may check labs to rule out contributors—for example, thyroid function, and other markers based on your history [3][4]. The North American Menopause Society and the Endocrine Society are clear that testosterone is not a routine fix to chase a number; testing is used to exclude problems, not to manufacture a diagnosis [4].
- The relationship and emotional context. Distance with a partner can be a cause, a consequence, or both. Naming it is not oversharing—it is clinically useful.
The goal of this review is a fuller picture, so that any suggestion fits *you* rather than a stereotype.
Local versus systemic: a key fork in the road
One of the most useful concepts to understand is the difference between local and systemic approaches—because they answer different questions.
Local (vaginal) approaches act mainly where they are applied. Non-hormonal options like long-acting vaginal moisturizers and lubricants are often a first step for comfort. For tissue changes, low-dose vaginal estrogen is a category that providers may discuss for GSM; because it is delivered locally, systemic absorption is low compared with pills taken by mouth [1][2]. This is often relevant for women whose *main* issue is comfort.
Systemic approaches circulate through the body. Systemic menopausal hormone therapy is considered for broader menopausal symptoms in appropriate candidates, with the decision shaped by age, time since menopause, and personal risk factors [2][5]. Separately, the conversation about *desire* sometimes includes options studied specifically for low sexual desire that causes distress—an area where guidelines emphasize careful candidate selection and honest expectations rather than guarantees [4].
There is no universal right answer. The right path depends on whether the dominant problem is comfort, desire, or both—and on your individual health profile.
On safety, age, and "is it too late?"
It is reasonable to want closeness at any age, and it is reasonable to want it to be safe. Two points are worth holding:
First, timing and individual risk matter in hormone conversations. Major menopause guidelines support individualized decisions rather than blanket rules, weighing benefits against risks like cardiovascular and breast considerations, especially as the years since menopause increase [2][5]. This is exactly why an independent provider—not an internet quiz—makes the call.
Second, local comfort options and non-hormonal strategies are part of the toolkit and are often discussed early, particularly when the chief concern is dryness or discomfort [1].
None of this is a promise that any particular option is right for you. A prescription, if any, is always decided by an independent licensed provider after review.
What to expect from the conversation
You do not need the right vocabulary to start. "Intimacy has changed and I want to understand why" is enough. Expect questions, possibly some labs, and a plan that may combine comfort measures, a discussion of hormonal options, and—when relevant—attention to mood, sleep, or the relationship itself. Expect, too, that the first step is information, not a prescription.
If compounded medication ever comes up in your care, know this: Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
*This article is educational and is not medical advice. It is not a diagnosis or a recommendation to use any specific medication. Talk with a licensed provider about your individual situation.*
Source: [1] The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society, [3] Female Sexual Dysfunction: ACOG Practice Bulletin, [4] Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Where Velri fits
Velri is a technology and coordination company—not a medical provider and not a pharmacy. What Velri can do is make the first step easier: coordinating lab work where appropriate, connecting you with an independent, licensed provider group for a confidential visit, and—*only if that provider prescribes*—coordinating with an independent licensed pharmacy. Whether any support is appropriate, and what form it takes, is always determined by the independent provider. The aim is simple: a calm, judgment-free way to ask the questions you have been carrying quietly.
